BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

...translation and inhibit stress granule formation. Biogen and Karyopharm Therapeutics Inc....
BioCentury | Jan 30, 2021
Regulation

Novartis subcutaneous mAb for MS, Incyte and Karyopharm oral cancer therapies backed by CHMP

...receive a positive opinion from EMA’s CHMP in January were drugs from Novartis, Incyte and Karyopharm...
...CHMP also recommended granting conditional marketing authorizations for an oral XPO1 inhibitor, Nexpovio selinexor from Karyopharm Therapeutics Inc....
...Exportin 1 Sandi Wong Kesimpta (subQ ofatumumab, subcutaneous ofatumumab) Xpovio, selinexor (ATG-010, KPT-330) Pemazyre, pemigatinib (INCB054828, INCB54828, IBI375) Novartis AG Incyte Corp. Karyopharm Therapeutics Inc. Exportin...
BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

...company’s lead program is ATG-010, licensed from Karyopharm Therapeutics Inc....
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...participation from Lilly Asia Ventures, Shiyu Capital, Summer Capital and existing investor South China Venture Capital. Karyopharm's...
...unresectable dedifferentiated liposarcoma. The therapy led to a significant benefit on progression-free survival (HR=0.70; p=0.023). Karyopharm...
...Inc. Cystic Fibrosis Foundation DBV Technologies S.A. European Medicines Agency (EMA) U.S. Food and Drug Administration (FDA) Gilead Sciences Inc. Galapagos N.V. Karyopharm Therapeutics Inc. Aurinia...
BioCentury | Jul 14, 2020
Regulation

GSK maintains lead in BCMA race with FDA panel’s recommendation

...option for patients who have failed three or four prior therapies is Xpovio selinexor from Karyopharm Therapeutics Inc....
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...45% to $27.05 on Monday. Karyopharm’s Xpovio gets DLBCL approval FDA approved Xpovio selinexor from Karyopharm Therapeutics Inc....
...the first drug the agency has indicated for both MM and DLBCL (see “FDA Approves Karyopharm’s...
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

...40% (see “ASCO Preview Carries MacroGenics to $1B Valuation”) . Karyopharm shares multiple myeloma data Karyopharm Therapeutics Inc....
...months for Velcade and dexamethasone alone in second-line or later multiple myeloma patients (HR=0.70; p=0.0075). Karyopharm...
...Programmed cell death 1 RET - Ret proto-oncogene XPO1 (CRM1) - Exportin 1 BioCentury Staff pralsetinib (BLU-667, CS3009) Karyopharm Therapeutics Inc. MacroGenics...
BioCentury | Apr 25, 2020
Management Tracks

Shawver named Silverback CEO; plus Incyte, Bicycle, Imvax, Chiasma, Aelin, Regenacy and Noscendo

...been Chiasma’s chief commercial officer until 2016. He was EVP and chief commercial officer of Karyopharm Therapeutics Inc....
BioCentury | Apr 8, 2020
Deals

COVID-19 roundup: U.S. to freeze WHO funding as Wellcome calls on CEOs to support $8B fund; plus Ridgeback-Emory, Karyopharm, IQVia and more

...than a billion earmarked for the global health organization. The day also saw Ridgeback and Karyopharm...
...replication and resulted in about a 4-log reduction in viral titers. Karyopharm repurposing MM drug Karyopharm Therapeutics Inc....
...disrupt the replication of SARS-CoV-2. In several animal models, Xpovio mediated anti-inflammatory and anti-viral effects, Karyopharm...
BioCentury | Mar 6, 2020
Finance

March 5 Quick Takes: Zogenix, Karyopharm, BridgeBio, Cinclus, Culture Biosciences, Deerfield-Melinta

...Zogenix, Karyopharm price follow-ons Zogenix Inc. (NASDAQ:ZGNX) and Karyopharm Therapeutics Inc. (NASDAQ:KPTI) each priced follow-on offerings, raising a...
...offering. The company’s Fintepla fenfluramine is under FDA review to treat seizure disorder Dravet syndrome. Karyopharm...
...continued to market its products since filing for Chapter 11 in December. BioCentury Staff BridgeBio Pharma Inc. Zogenix Inc. Karyopharm Therapeutics Inc....
Items per page:
1 - 10 of 157
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

...translation and inhibit stress granule formation. Biogen and Karyopharm Therapeutics Inc....
BioCentury | Jan 30, 2021
Regulation

Novartis subcutaneous mAb for MS, Incyte and Karyopharm oral cancer therapies backed by CHMP

...receive a positive opinion from EMA’s CHMP in January were drugs from Novartis, Incyte and Karyopharm...
...CHMP also recommended granting conditional marketing authorizations for an oral XPO1 inhibitor, Nexpovio selinexor from Karyopharm Therapeutics Inc....
...Exportin 1 Sandi Wong Kesimpta (subQ ofatumumab, subcutaneous ofatumumab) Xpovio, selinexor (ATG-010, KPT-330) Pemazyre, pemigatinib (INCB054828, INCB54828, IBI375) Novartis AG Incyte Corp. Karyopharm Therapeutics Inc. Exportin...
BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

...company’s lead program is ATG-010, licensed from Karyopharm Therapeutics Inc....
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...participation from Lilly Asia Ventures, Shiyu Capital, Summer Capital and existing investor South China Venture Capital. Karyopharm's...
...unresectable dedifferentiated liposarcoma. The therapy led to a significant benefit on progression-free survival (HR=0.70; p=0.023). Karyopharm...
...Inc. Cystic Fibrosis Foundation DBV Technologies S.A. European Medicines Agency (EMA) U.S. Food and Drug Administration (FDA) Gilead Sciences Inc. Galapagos N.V. Karyopharm Therapeutics Inc. Aurinia...
BioCentury | Jul 14, 2020
Regulation

GSK maintains lead in BCMA race with FDA panel’s recommendation

...option for patients who have failed three or four prior therapies is Xpovio selinexor from Karyopharm Therapeutics Inc....
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...45% to $27.05 on Monday. Karyopharm’s Xpovio gets DLBCL approval FDA approved Xpovio selinexor from Karyopharm Therapeutics Inc....
...the first drug the agency has indicated for both MM and DLBCL (see “FDA Approves Karyopharm’s...
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

...40% (see “ASCO Preview Carries MacroGenics to $1B Valuation”) . Karyopharm shares multiple myeloma data Karyopharm Therapeutics Inc....
...months for Velcade and dexamethasone alone in second-line or later multiple myeloma patients (HR=0.70; p=0.0075). Karyopharm...
...Programmed cell death 1 RET - Ret proto-oncogene XPO1 (CRM1) - Exportin 1 BioCentury Staff pralsetinib (BLU-667, CS3009) Karyopharm Therapeutics Inc. MacroGenics...
BioCentury | Apr 25, 2020
Management Tracks

Shawver named Silverback CEO; plus Incyte, Bicycle, Imvax, Chiasma, Aelin, Regenacy and Noscendo

...been Chiasma’s chief commercial officer until 2016. He was EVP and chief commercial officer of Karyopharm Therapeutics Inc....
BioCentury | Apr 8, 2020
Deals

COVID-19 roundup: U.S. to freeze WHO funding as Wellcome calls on CEOs to support $8B fund; plus Ridgeback-Emory, Karyopharm, IQVia and more

...than a billion earmarked for the global health organization. The day also saw Ridgeback and Karyopharm...
...replication and resulted in about a 4-log reduction in viral titers. Karyopharm repurposing MM drug Karyopharm Therapeutics Inc....
...disrupt the replication of SARS-CoV-2. In several animal models, Xpovio mediated anti-inflammatory and anti-viral effects, Karyopharm...
BioCentury | Mar 6, 2020
Finance

March 5 Quick Takes: Zogenix, Karyopharm, BridgeBio, Cinclus, Culture Biosciences, Deerfield-Melinta

...Zogenix, Karyopharm price follow-ons Zogenix Inc. (NASDAQ:ZGNX) and Karyopharm Therapeutics Inc. (NASDAQ:KPTI) each priced follow-on offerings, raising a...
...offering. The company’s Fintepla fenfluramine is under FDA review to treat seizure disorder Dravet syndrome. Karyopharm...
...continued to market its products since filing for Chapter 11 in December. BioCentury Staff BridgeBio Pharma Inc. Zogenix Inc. Karyopharm Therapeutics Inc....
Items per page:
1 - 10 of 157